GLP1 agonists: FDA investigates suicide risk
Following in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.<br /><br /><br />
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 997 entries already.
Following in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.<br /><br /><br />
Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd. <br /><br />
Italian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.
Hoffmann-La Roche AG has published details on <i>the mechanism of action of its Phase I antibiotic Zosurabalpin</i> (RG6006) that kills the carbapenem-resistant bug<i> Acinetobacter baumannii</i>. <br />.
Following its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal. <div title="Page 1" class="page"><div class="layoutArea"><div class="column"></div></div></div>
Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn.
Cambridge-based Metrion Biosciences Ltd has secured £3.5m in new equity financing – led by Maven Capital Partners and a £1m contribution from existing investor, Gresham House Ventures.
Swiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVacc’s preclinical <i>Staphylococcus aureus vaccine </i><span style="caret-color: rgb(33, 33, 33); color: rgb(33, 33, 33); font-family: Arial, sans-serif; font-size: 13.333333015441895px; font-style: […]
The French Republicans have tabled a bill in the National Assembly aimed at banning the commercialisation of cell-based meat in France.
Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318.